Sight Sciences to Present at the Upcoming Piper Sandler Virtual Ophthalmology & Diabetes Symposium
Sight Sciences, Inc. (Nasdaq: SGHT) has announced its participation in the Piper Sandler Virtual Ophthalmology & Diabetes Symposium scheduled for May 23, 2022, at 10:00 AM PT. This event will feature a fireside chat with the company's management, accessible via webcast on their investor website. Sight Sciences is dedicated to innovating eyecare solutions to improve patient treatment, particularly through its OMNI® Surgical System for glaucoma and TearCare® System for dry eye disease, both aimed at enhancing patient care and addressing significant eye health challenges.
- None.
- None.
MENLO PARK, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced plans to participate in the upcoming Piper Sandler Virtual Ophthalmology & Diabetes Symposium.
Sight Sciences’ management is scheduled to participate in a fireside chat Monday, May 23, 2022, at 10:00am PT. Interested parties may access a live and archived webcast of the fireside chat on the “Investors” section of the company’s website at: https://investors.sightsciences.com/.
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is a minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the world’s leading cause of irreversible blindness. The Company’s TearCare® System is 510(k) cleared for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), enabling office-based clearance of gland obstructions by physicians to address the leading cause of dry eye disease.
For more information, visit www.sightsciences.com.
OMNI® and TearCare® are registered trademarks of Sight Sciences.
© 2022 Sight Sciences. All rights reserved.
Media contact:
Shay Smith
Health+Commerce
707.971.9779
shay@healthandcommerce.com
Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com
FAQ
When is Sight Sciences participating in the Piper Sandler Virtual Ophthalmology & Diabetes Symposium?
How can I access the Sight Sciences fireside chat?
What products does Sight Sciences focus on?
What is the ticker symbol for Sight Sciences?
What is the main goal of Sight Sciences?
